The collaboration leverages the Kajimura Lab’s world-class expertise in adipose tissue biology
Neurodon and Kajimura Lab’s work together has the potential to deliver therapeutics for diabetes, obesity, and insulin resistance.
Russell Dahl, Ph.D., Neurodon Founder, and CEO, said, “As a patient-focused company, Neurodon was launched to deliver disease-modifying therapies for unmet diseases. Shingo has made fundamental discoveries in adipose tissue adaptation and thermogenesis that have vast potential for diabetes and obesity. We are delighted to collaborate with a prominent leader in metabolic research with the aim to validate new therapeutic candidates with novel mechanisms and targets — ultimately providing new options for patients.”
Shingo Kajimura, M.D., a professor in the Division of Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center as well as the Department of Medicine at Harvard Medical School, said, “We are excited about the collaboration to explore the therapeutic potential of SERCA activators in metabolic disorders, including obesity, diabetes, and liver diseases.”